NCT04348747: Dendritic Cell Vaccines Against Her2/Her3, Cytokine Modulation Regimen, and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

NCT04348747
Breast Cancer Type: HER2+, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic antibody, Misc Inhibitor

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have at least one untreated brain metastasis; Patients with any brain metastasis greater than or equal to 3.0 cm or causing symptoms must have previously been treated with local therapy (i.e. radiation or surgical resection, etc.)
Exclusions: Patients with leptomeningeal disease
https://ClinicalTrials.gov/show/NCT04348747

Comments are closed.

Up ↑